Spero Therapeutics announced its financial results for the first quarter ended March 31, 2025, on May 13, 2025. The company reported a net loss of $13.9 million for the quarter, an increase from the $12.7 million net loss in the same period of 2024.
As of March 31, 2025, Spero held $48.9 million in cash and cash equivalents. The company estimates its cash runway will extend into the second quarter of 2026, supported by expected non-contingent milestone payments from GSK.
These milestone payments include a final $23.8 million installment expected in Q3 2025. The company's top priority remains the successful execution of the tebipenem HBr clinical program, with preparation underway for the pre-specified interim analysis of the PIVOT-PO trial during Q2 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.